Literature DB >> 24940827

Metabolomic Profiling of Autoimmune Hepatitis: The Diagnostic Utility of Nuclear Magnetic Resonance Spectroscopy.

Jia-Bo Wang1, Shi-Biao Pu1,2, Ying Sun3, Zhong-Feng Li4, Ming Niu1, Xian-Zhong Yan5, Yan-Ling Zhao1, Li-Feng Wang6, Xue-Mei Qin7, Zhi-Jie Ma8, Ya-Ming Zhang1, Bao-Sen Li3, Sheng-Qiang Luo9, Man Gong9, Yong-Qiang Sun9, Zheng-Sheng Zou3, Xiao-He Xiao9.   

Abstract

Autoimmune hepatitis (AIH) is often confused with other liver diseases because of their shared nonspecific symptoms and serological and histological overlap. This study compared the plasma metabolomic profiles of patients with AIH, primary biliary cirrhosis (PBC), PBC/AIH overlap syndrome (OS), and drug-induced liver injury (DILI) with those of healthy subjects to identify potential biomarkers of AIH. Metabolomic profiling and biomarker screening were performed using proton nuclear magnetic resonance spectroscopy (1H NMR) coupled with a partial least-squares discriminant analysis. Compared with the levels in healthy volunteers and other liver disease patients, AIH patients exhibited relatively high levels of plasma pyruvate, lactate, acetate, acetoacetate, and glucose. Such metabolites are typically related to energy metabolism alterations and may be a sign of metabolic conversion to the aerobic glycolysis phenotype of excessive immune activation. Increased aromatic amino acids and decreased branched-chain amino acids were found in the plasma of AIH patients. The whole NMR profiles were stepwise-reduced, and nine metabolomic biomarkers having the greatest significance in the discriminant analysis were obtained. The diagnostic utility of the selected metabolites was assessed, and these biomarkers achieved good sensitivity, specificity, and accuracy (all above 93%) in distinguishing AIH from PBC, DILI, and OS. This report is the first to present the metabolic phenotype of AIH and the potential utility of 1H NMR metabolomics in the diagnosis of AIH.

Entities:  

Keywords:  Autoimmune hepatitis; NMR; biomarker; diagnosis; metabolomics

Year:  2014        PMID: 24940827     DOI: 10.1021/pr500462f

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  24 in total

1.  Evidence chain-based causality identification in herb-induced liver injury: exemplification of a well-known liver-restorative herb Polygonum multiflorum.

Authors:  Jiabo Wang; Zhijie Ma; Ming Niu; Yun Zhu; Qingsheng Liang; Yanling Zhao; Jingyuan Song; Zhaofang Bai; Yaming Zhang; Ping Zhang; Na Li; Yakun Meng; Qi Li; Lushan Qin; Guangju Teng; Junling Cao; Baosen Li; Shilin Chen; Yonggang Li; Zhengsheng Zou; Honghao Zhou; Xiaohe Xiao
Journal:  Front Med       Date:  2015-10-12       Impact factor: 4.592

Review 2.  Nuclear magnetic resonance based metabolomics and liver diseases: Recent advances and future clinical applications.

Authors:  Roland Amathieu; Mohamed Nawfal Triba; Corentine Goossens; Nadia Bouchemal; Pierre Nahon; Philippe Savarin; Laurence Le Moyec
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 3.  Metabonomic window into hepatitis B virus-related hepatic diseases.

Authors:  Qiang Hou; Zhi-Jun Duan
Journal:  World J Hepatol       Date:  2016-01-08

Review 4.  Novel approaches to liver disease diagnosis and modeling.

Authors:  André G Oliveira; Romina Fiorotto
Journal:  Transl Gastroenterol Hepatol       Date:  2021-04-05

5.  Metabolomics profiles of patients with Wilson disease reveal a distinct metabolic signature.

Authors:  Gaurav V Sarode; Kyoungmi Kim; Dorothy A Kieffer; Noreene M Shibata; Tomas Litwin; Anna Czlonkowska; Valentina Medici
Journal:  Metabolomics       Date:  2019-03-12       Impact factor: 4.290

6.  Metabolic Characterization of Advanced Liver Fibrosis in HCV Patients as Studied by Serum 1H-NMR Spectroscopy.

Authors:  Nieves Embade; Zoe Mariño; Tammo Diercks; Ainara Cano; Sabela Lens; Diana Cabrera; Miquel Navasa; Juan M Falcón-Pérez; Joan Caballería; Azucena Castro; Jaume Bosch; José M Mato; Oscar Millet
Journal:  PLoS One       Date:  2016-05-09       Impact factor: 3.240

Review 7.  Biomarkers in DILI: One More Step Forward.

Authors:  Mercedes Robles-Díaz; Inmaculada Medina-Caliz; Camilla Stephens; Raúl J Andrade; M Isabel Lucena
Journal:  Front Pharmacol       Date:  2016-08-22       Impact factor: 5.810

8.  Serum Metabolomics Analysis Reveals a Distinct Metabolic Profile of Patients with Primary Biliary Cholangitis.

Authors:  Juan Hao; Tao Yang; Yang Zhou; Guo-Yuan Gao; Feng Xing; Yuan Peng; Yan-Yan Tao; Cheng-Hai Liu
Journal:  Sci Rep       Date:  2017-04-11       Impact factor: 4.379

9.  Maresin 1, a Proresolving Lipid Mediator, Mitigates Carbon Tetrachloride-Induced Liver Injury in Mice.

Authors:  Ruidong Li; Yaxin Wang; Ende Zhao; Ke Wu; Wei Li; Liang Shi; Di Wang; Gengchen Xie; Yuping Yin; Meizhou Deng; Peng Zhang; Kaixiong Tao
Journal:  Oxid Med Cell Longev       Date:  2016-01-06       Impact factor: 6.543

Review 10.  Pharmacometabolomics-aided Pharmacogenomics in Autoimmune Disease.

Authors:  Theodora Katsila; Evangelia Konstantinou; Ioanna Lavda; Harilaos Malakis; Ioanna Papantoni; Lamprini Skondra; George P Patrinos
Journal:  EBioMedicine       Date:  2016-02-02       Impact factor: 8.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.